Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)
December 22, 2017 08:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
Kura Oncology Logo
Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
April 05, 2017 08:00 ET | Kura Oncology, Inc.
LA JOLLA, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Logo
Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results
March 07, 2017 16:05 ET | Kura Oncology, Inc.
LA JOLLA, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Logo
Kura Oncology to Participate in Three Upcoming Investor Conferences
February 09, 2017 16:05 ET | Kura Oncology, Inc.
LA JOLLA, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...
Kura Oncology Logo
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
January 17, 2017 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase...
Kura Oncology Logo
Kura Oncology Appoints Steven Stein, M.D. to Board of Directors
January 03, 2017 16:05 ET | Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced the appointment of Steven H. Stein, M.D., to its...
Kura Oncology Logo
Kura Oncology to Participate in the 5th Annual Gateway Conference
September 02, 2016 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Gateway...
Kura Oncology Logo
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
June 16, 2016 17:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced the first patient has been dosed in a Phase 2...
Kura Oncology Logo
Kura Oncology to Participate in the 2016 JMP Life Sciences Conference
June 14, 2016 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 JMP Life Sciences...
Kura Oncology Logo
Kura Oncology to Participate in the Jefferies 2016 Healthcare Conference
June 03, 2016 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the Jefferies 2016...